Where does ATXS stock trade?

Astria Therapeutics Inc. (ATXS) is listed on NASDAQ.

What sector and industry is ATXS in?

Astria Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.

When did Astria Therapeutics Inc. go public?

Astria Therapeutics Inc. (ATXS) completed its IPO in 2015.

What are analysts saying about ATXS?

Astria Therapeutics Inc. has had 7 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Neutral on 2025-11-12. Recent price targets range from $1800.00 to $4700.00.

What companies are similar to ATXS?

Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ATXS side-by-side with any of them on Quantisnow.

How can I track ATXS on Quantisnow?

Quantisnow aggregates Astria Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ATXS to receive live email and push alerts on every new disclosure.

ATXS

NASDAQ

Astria Therapeutics Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2015

$12.56+0.07 (+0.56%)

News25/Ratings7

Price$12.56+0.41 (+3.37%)

2025-10-202026-01-23

News · 26 weeks510%

2025-12-072026-05-31

Mix090d

No activity.

Latest news

25 items

110dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Astria Therapeutics Inc.
SCHEDULE 13G/A - Astria Therapeutics, Inc. (0001454789) (Subject)
113dSEC
Amendment: SEC Form SCHEDULE 13D/A filed by Astria Therapeutics Inc.
SCHEDULE 13D/A - Astria Therapeutics, Inc. (0001454789) (Subject)
121dSEC
SEC Form 15-12G filed by Astria Therapeutics Inc.
15-12G - Astria Therapeutics, Inc. (0001454789) (Filer)
126dSEC
Amendment: SEC Form SCHEDULE 13D/A filed by Astria Therapeutics Inc.
SCHEDULE 13D/A - Astria Therapeutics, Inc. (0001454789) (Subject)
126dSEC
SEC Form EFFECT filed by Astria Therapeutics Inc.
EFFECT - Astria Therapeutics, Inc. (0001454789) (Filer)
126dSEC
SEC Form EFFECT filed by Astria Therapeutics Inc.
EFFECT - Astria Therapeutics, Inc. (0001454789) (Filer)
126dSEC
SEC Form EFFECT filed by Astria Therapeutics Inc.
EFFECT - Astria Therapeutics, Inc. (0001454789) (Filer)
126dSEC
SEC Form EFFECT filed by Astria Therapeutics Inc.
EFFECT - Astria Therapeutics, Inc. (0001454789) (Filer)
126dSEC
SEC Form EFFECT filed by Astria Therapeutics Inc.
EFFECT - Astria Therapeutics, Inc. (0001454789) (Filer)
126dSEC
SEC Form EFFECT filed by Astria Therapeutics Inc.
EFFECT - Astria Therapeutics, Inc. (0001454789) (Filer)
128dSEC
Amendment: SEC Form 25-NSE/A filed by Astria Therapeutics Inc.
25-NSE/A - Astria Therapeutics, Inc. (0001454789) (Subject)
131dSEC
SEC Form S-8 POS filed by Astria Therapeutics Inc.
S-8 POS - Astria Therapeutics, Inc. (0001454789) (Filer)
131dSEC
SEC Form S-8 POS filed by Astria Therapeutics Inc.
S-8 POS - Astria Therapeutics, Inc. (0001454789) (Filer)
131dSEC
SEC Form S-8 POS filed by Astria Therapeutics Inc.
S-8 POS - Astria Therapeutics, Inc. (0001454789) (Filer)
131dSEC
SEC Form S-8 POS filed by Astria Therapeutics Inc.
S-8 POS - Astria Therapeutics, Inc. (0001454789) (Filer)
131dSEC
SEC Form S-8 POS filed by Astria Therapeutics Inc.
S-8 POS - Astria Therapeutics, Inc. (0001454789) (Filer)
131dSEC
SEC Form S-8 POS filed by Astria Therapeutics Inc.
S-8 POS - Astria Therapeutics, Inc. (0001454789) (Filer)
131dSEC
SEC Form S-8 POS filed by Astria Therapeutics Inc.
S-8 POS - Astria Therapeutics, Inc. (0001454789) (Filer)
131dSEC
SEC Form S-8 POS filed by Astria Therapeutics Inc.
S-8 POS - Astria Therapeutics, Inc. (0001454789) (Filer)
131dSEC
SEC Form S-8 POS filed by Astria Therapeutics Inc.
S-8 POS - Astria Therapeutics, Inc. (0001454789) (Filer)
131dSEC
SEC Form S-8 POS filed by Astria Therapeutics Inc.
S-8 POS - Astria Therapeutics, Inc. (0001454789) (Filer)
131dSEC
SEC Form S-8 POS filed by Astria Therapeutics Inc.
S-8 POS - Astria Therapeutics, Inc. (0001454789) (Filer)
131dSEC
SEC Form S-8 POS filed by Astria Therapeutics Inc.
S-8 POS - Astria Therapeutics, Inc. (0001454789) (Filer)
131dINSIDER
Director Violin Jonathan returned 263,321 shares to the company, closing all direct ownership in the company (SEC Form 4)
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)
131dINSIDER
SEC Form 4 filed by Chief Medical Officer Morabito Christopher
4 - Astria Therapeutics, Inc. (0001454789) (Issuer)

Analyst ratings

Last 7

Nov 12Cantor Fitzgerald•Update
Neutral--
Sep 17H.C. Wainwright•Update
Buy$20.00$16.00▲ 59.2%
Apr 29Cantor Fitzgerald•Update
Overweight$47.00▲ 274%
Jan 31JMP Securities•Update
Mkt Outperform$26.00▲ 107%
Jul 29TD Cowen•Update
Buy$35.00▲ 179%
Mar 28Evercore ISI•Update
Outperform$18.00▲ 43.3%
Sep 29Jefferies•Update
Buy$20.00▲ 59.2%

Options

1 expiration

Jul 17, 202643d

1 exp · 3

Callsstrike · last · iv · Δ

7.506.50--
12.500.85--

Putsstrike · last · iv · Δ

10.000.15--

Peers

Quick links

ATXS FAQ

6 questions

Where does ATXS stock trade?
Astria Therapeutics Inc. (ATXS) is listed on NASDAQ.
What sector and industry is ATXS in?
Astria Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
When did Astria Therapeutics Inc. go public?
Astria Therapeutics Inc. (ATXS) completed its IPO in 2015.
What are analysts saying about ATXS?
Astria Therapeutics Inc. has had 7 recent analyst actions on file. The most recent action was from Cantor Fitzgerald: Neutral on 2025-11-12. Recent price targets range from $1800.00 to $4700.00.
What companies are similar to ATXS?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ATXS side-by-side with any of them on Quantisnow.
How can I track ATXS on Quantisnow?
Quantisnow aggregates Astria Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ATXS to receive live email and push alerts on every new disclosure.